SE516133C2 - Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation - Google Patents

Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation

Info

Publication number
SE516133C2
SE516133C2 SE9900677A SE9900677A SE516133C2 SE 516133 C2 SE516133 C2 SE 516133C2 SE 9900677 A SE9900677 A SE 9900677A SE 9900677 A SE9900677 A SE 9900677A SE 516133 C2 SE516133 C2 SE 516133C2
Authority
SE
Sweden
Prior art keywords
group
positions
lower alkyl
compound
iodine
Prior art date
Application number
SE9900677A
Other languages
English (en)
Swedish (sv)
Other versions
SE9900677D0 (sv
SE9900677L (sv
Inventor
Lennart Moeller
Jan Bergman
Original Assignee
Lundblad Leif J I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundblad Leif J I filed Critical Lundblad Leif J I
Priority to SE9900677A priority Critical patent/SE516133C2/sv
Publication of SE9900677D0 publication Critical patent/SE9900677D0/xx
Priority to CNB008041083A priority patent/CN1151790C/zh
Priority to JP2000600650A priority patent/JP2002537338A/ja
Priority to AU33398/00A priority patent/AU3339800A/en
Priority to US09/914,300 priority patent/US6472395B1/en
Priority to AT00911532T priority patent/ATE266406T1/de
Priority to ES00911532T priority patent/ES2220427T3/es
Priority to PCT/SE2000/000339 priority patent/WO2000050039A1/en
Priority to EP00911532A priority patent/EP1154772B1/en
Priority to RU2001126044/15A priority patent/RU2242975C2/ru
Priority to DE60010665T priority patent/DE60010665T2/de
Publication of SE9900677L publication Critical patent/SE9900677L/
Publication of SE516133C2 publication Critical patent/SE516133C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9900677A 1999-02-25 1999-02-25 Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation SE516133C2 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9900677A SE516133C2 (sv) 1999-02-25 1999-02-25 Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation
DE60010665T DE60010665T2 (de) 1999-02-25 2000-02-18 Mittel zur verwendung in der transplantation
US09/914,300 US6472395B1 (en) 1999-02-25 2000-02-18 Agent for use in transplantation
JP2000600650A JP2002537338A (ja) 1999-02-25 2000-02-18 移植において用いるための薬剤
AU33398/00A AU3339800A (en) 1999-02-25 2000-02-18 Agent for use in transplantation
CNB008041083A CN1151790C (zh) 1999-02-25 2000-02-18 用于移植术的药剂
AT00911532T ATE266406T1 (de) 1999-02-25 2000-02-18 Mittel zur verwendung in der transplantation
ES00911532T ES2220427T3 (es) 1999-02-25 2000-02-18 Agente para uso en trasplantes.
PCT/SE2000/000339 WO2000050039A1 (en) 1999-02-25 2000-02-18 Agent for use in transplantation
EP00911532A EP1154772B1 (en) 1999-02-25 2000-02-18 Agent for use in transplantation
RU2001126044/15A RU2242975C2 (ru) 1999-02-25 2000-02-18 Агент для использования при трансплантации

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900677A SE516133C2 (sv) 1999-02-25 1999-02-25 Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation

Publications (3)

Publication Number Publication Date
SE9900677D0 SE9900677D0 (sv) 1999-02-25
SE9900677L SE9900677L (sv) 2000-08-26
SE516133C2 true SE516133C2 (sv) 2001-11-19

Family

ID=20414629

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900677A SE516133C2 (sv) 1999-02-25 1999-02-25 Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation

Country Status (11)

Country Link
US (1) US6472395B1 (ru)
EP (1) EP1154772B1 (ru)
JP (1) JP2002537338A (ru)
CN (1) CN1151790C (ru)
AT (1) ATE266406T1 (ru)
AU (1) AU3339800A (ru)
DE (1) DE60010665T2 (ru)
ES (1) ES2220427T3 (ru)
RU (1) RU2242975C2 (ru)
SE (1) SE516133C2 (ru)
WO (1) WO2000050039A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465466B1 (en) * 1995-12-22 2002-10-15 Leif J. I. Lundblad Uses of indolo-2 [2,3b] -quinoxalines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
SE9302431D0 (sv) 1993-07-16 1993-07-16 Ab Astra Use of indenoindole compounds
US5859001A (en) 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
SE504289C2 (sv) * 1994-06-23 1996-12-23 Leif J I Lundblad Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
SE504862C2 (sv) 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
US6635626B1 (en) * 1997-08-25 2003-10-21 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
US6333327B2 (en) * 2000-02-18 2001-12-25 Leif J. I. Lundblad Method for the treatment of Multiple Sclerosis

Also Published As

Publication number Publication date
EP1154772B1 (en) 2004-05-12
EP1154772A1 (en) 2001-11-21
ES2220427T3 (es) 2004-12-16
RU2242975C2 (ru) 2004-12-27
CN1151790C (zh) 2004-06-02
CN1341023A (zh) 2002-03-20
US6472395B1 (en) 2002-10-29
DE60010665D1 (de) 2004-06-17
SE9900677D0 (sv) 1999-02-25
ATE266406T1 (de) 2004-05-15
SE9900677L (sv) 2000-08-26
AU3339800A (en) 2000-09-14
JP2002537338A (ja) 2002-11-05
DE60010665T2 (de) 2005-05-19
WO2000050039A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
Zschiedrich et al. Targeting mTOR signaling can prevent the progression of FSGS
Minor et al. Hypothermic reconditioning by gaseous oxygen improves survival after liver transplantation in the pig
Elimadi et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function
Beuers et al. Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis.
Sappington et al. Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated caco-2 enterocytic monolayers
Schoenberg et al. Studies on the oxygen radical mechanism involved in the small intestinal reperfusion damage
Cox et al. Protoporphyria
Xiong et al. Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis
Nguyen et al. Polyethylene glycol-superoxide dismutase inhibits lipid peroxidation in hepatic ischemia/reperfusion injury
Gulmen et al. Tezosentan reduces the renal injury induced by abdominal aortic ischemia-reperfusion in rats
Peck et al. Protective effect of nifedipine in the hypoxic perfused cat liver
Valencia et al. Anomalous inhibitory circuits in cortical tubers of human tuberous sclerosis complex associated with refractory epilepsy: aberrant expression of parvalbumin and calbindin-D28k in dysplastic cortex
SE516133C2 (sv) Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation
Inci et al. Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model
Minor et al. Reduction of renal preservation/reperfusion injury by controlled hyperthermia during ex vivo machine perfusion
Wang et al. Melatonin, a potent regulator of hemeoxygenase‐1, reduces cardiopulmonary bypass‐induced renal damage in rats
Shushimita et al. Protection against renal ischemia–reperfusion injury through hormesis? Dietary intervention versus cold exposure
Snedeker et al. Dimethyl sulfoxide as a cryoprotective agent for freezing bovine semen
Makowka et al. The effect of liver cytosol on hepatic regeneration and tumor growth
Tselepidis et al. Liver injury after ischemia and reperfusion: the role of oxygen free radicals
Coward Effects of actinomycin D on regeneration give evidence of sequential gene activation
Uchida et al. Induction of specific stress response increases resistance of rat liver allografts to cold ischemia and reperfusion injury
Banz et al. Dextran sulfate modulates MAP kinase signaling and reduces endothelial injury in a rat aortic clamping model
Gallagher The effect of sporidesmin on liver enzyme systems
Elvin et al. Anti-tumour activity of novel adducts of ascorbic acid with aldehydes

Legal Events

Date Code Title Description
NUG Patent has lapsed